Schrödinger Names Software Executive Oberoi to Board of Directors
20 May 2022 - - US-based life sciences and materials science company Schrödinger, Inc. (NASDAQ: SDGR), whose physics-based software platform is used for therapeutics and materials discovery, has appointed Arun Oberoi to its board of directors, the company said.

Oberoi will serve as a member of the audit committee.

Oberoi is the former executive vice president, global sales and services, of Red Hat, the world's provider of enterprise open source software solutions, where he served from 2012 to 2021.

Prior to Red Hat, Oberoi played critical leadership roles in building software businesses spanning a diverse range of companies, from startups to midsized and Fortune 100 enterprises.

He was chief executive officer of Viridity Software from 2010 to 2012 and chief executive officer of Aveksa from 2008 to 2010.

He served as an executive vice president of global sales and technical services of Micromuse from 2004 to 2008.

Prior to joining Micromuse, Oberoi held a series of senior executive positions at Hewlett-Packard, including vice president and general manager, worldwide corporate accounts and industries, sales and marketing.

Oberoi serves on the board of directors of Deeplite as well as Proofpoint and Talend, which are both portfolio companies of Thoma Bravo, L.P.

Oberoi received his bachelor's degree from Delhi University and has an MBA from the Kellogg School of Management at Northwestern University.

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods.

The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world.

Schrödinger's multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 700 employees and is engaged with customers and collaborators in more than 70 countries.